Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor
about
Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation.FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model.Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis.A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor.Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase.Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint WorkshopNuclear receptor small heterodimer partner in apoptosis signaling and liver cancer.Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptorsInactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells.The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apc (min/+) mice through enhancing Wnt signaling.
P2860
Q33687018-C3277502-4BF1-4214-980F-5B5728B6B6F2Q34440796-B8E29326-2703-4A00-AA04-036F69049FBEQ34465146-1A38DD69-8C15-430F-84D4-6FE7B31FE569Q35675180-8D1E5974-F09C-4FE8-9AA4-1251F19D2C3DQ35864946-BD2538B4-B01B-4597-87F2-B0D85FBC8DABQ36297726-89E9BABA-F752-46AE-9271-6CE8831B6B01Q36987260-9BEBF84C-F02C-4B99-91CC-42D14B28D867Q38161329-65C16BB1-C5AF-4E27-9830-86AFBDE0C5A0Q42253372-720EBD49-EAE5-4403-9A57-ED464B5B1CD9Q52900266-6430C123-DCE4-4920-AE64-5D1A6B024EF0Q53232812-6E8B8F13-125A-42EC-BBD8-0B3857C5BE38
P2860
Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@ast
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@en
type
label
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@ast
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@en
prefLabel
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@ast
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@en
P2093
P2860
P356
P1433
P1476
Sodium taurocholate inhibits i ...... on of the farnesoid X receptor
@en
P2093
Darcey L H Smith
Kashif Ahmed
Pavitra Keshavan
Stephen D Zucker
P2860
P304
P356
10.1093/CARCIN/BGQ050
P407
P50
P577
2010-03-01T00:00:00Z